Innospec (IOSP) Expected to Announce Earnings on Thursday

Key Points

• Innospec will report Q1 2026 results after the market close on May 7, with analysts projecting earnings of $1.04 per share and revenue of about $435 million and a conference call scheduled for May 8 at 9:00 AM ET.
• In the prior quarter Innospec beat EPS expectations ($1.50 vs. $1.26) but saw revenue decline year-over-year and miss estimates, and analysts forecast roughly $5 EPS for the current fiscal year and $6 for next year.
• The stock opened at $75.61 (down 1.3%), market cap about $1.88 billion and a P/E of 16.16; insiders sold 4,989 shares (~$391,889) in the past three months and now own 1.45% of the company.

Innospec (NASDAQ:IOSP - Get Free Report) is projected to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Innospec to post earnings of $1.04 per share and revenue of $434.9860 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:00 AM ET.

Innospec (NASDAQ:IOSP - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The specialty chemicals company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.26 by $0.24. The company had revenue of $455.60 million during the quarter, compared to the consensus estimate of $460.87 million. Innospec had a net margin of 6.56% and a return on equity of 10.18%. The company's quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.41 EPS. On average, analysts expect Innospec to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Innospec Stock Down 1.3%

Shares of IOSP stock opened at $75.61 on Thursday. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 16.16, a price-to-earnings-growth ratio of 2.09 and a beta of 0.90. Innospec has a 52 week low of $65.51 and a 52 week high of $95.55. The firm has a 50 day moving average of $73.92 and a 200-day moving average of $76.50.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Zacks Research raised shares of Innospec from a "strong sell" rating to a "hold" rating in a research report on Friday, April 24th. Weiss Ratings raised shares of Innospec from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, February 19th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of "Hold".

Insider Transactions at Innospec

In other Innospec news, SVP David B. Jones sold 1,028 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $75.64, for a total value of $77,757.92. Following the transaction, the senior vice president owned 14,693 shares in the company, valued at approximately $1,111,378.52. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Landless sold 594 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $76.56, for a total value of $45,476.64. Following the completion of the transaction, the director owned 7,632 shares in the company, valued at approximately $584,305.92. The trade was a 7.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,989 shares of company stock worth $391,889 in the last three months. Insiders own 1.45% of the company's stock.

Institutional Investors Weigh In On Innospec

Institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its holdings in shares of Innospec by 1,159.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 529 shares of the specialty chemicals company's stock worth $44,000 after acquiring an additional 487 shares during the last quarter. Danske Bank A S acquired a new position in Innospec during the 3rd quarter valued at about $46,000. State of Wyoming boosted its stake in Innospec by 27.5% during the 2nd quarter. State of Wyoming now owns 801 shares of the specialty chemicals company's stock valued at $67,000 after purchasing an additional 173 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Innospec by 26.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,665 shares of the specialty chemicals company's stock valued at $130,000 after purchasing an additional 348 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its stake in Innospec by 11.5% during the 1st quarter. Baird Financial Group Inc. now owns 2,170 shares of the specialty chemicals company's stock valued at $206,000 after purchasing an additional 223 shares during the last quarter. Institutional investors and hedge funds own 96.64% of the company's stock.

About Innospec

Innospec Incorporated NASDAQ: IOSP is a global specialty chemicals company headquartered in Cleveland, Ohio. The company operates through three principal business segments: Fuel Specialties, Oilfield Services, and Performance Chemicals. In the Fuel Specialties segment, Innospec develops and supplies additives designed to enhance octane levels, improve combustion efficiency, reduce emissions and prevent deposit formation in gasoline and diesel engines. Its Oilfield Services division provides chemical technologies—such as surfactants, corrosion inhibitors and demulsifiers—to support exploration, drilling, production optimization and enhanced oil recovery operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.